Japan · Delayed Price · Currency is JPY Chugai Pharmaceutical Earnings Call Transcripts
Fiscal Year 2026
-
Q1 FY2026 delivered double-digit growth in revenue, operating profit, and net income, driven by strong Hemlibra and Nemluvio exports, new product launches, and higher royalty income. Performance was in line with expectations, with continued investment in innovation and pipeline advancement.
Fiscal Year 2025
-
Record FY2025 results with revenue up 7.5% and core operating profit up 12.1%, driven by strong exports and royalty income. FY2026 guidance projects further growth, with continued investment in R&D, digital transformation, and global partnerships.
-
Q3 FY2025 delivered strong revenue and profit growth, driven by robust domestic and overseas sales, especially from Hemlibra, Actemra, and new product launches. Strategic acquisitions and pipeline progress support a positive outlook, with full-year results expected to exceed last year.
-
Second quarter 2025 saw revenue and profit growth driven by strong domestic and overseas sales, especially for Actemra and Hemlibra. Five early-stage R&D projects were discontinued to focus resources, and a major JPY 80 billion R&D facility investment was announced. Guidance for key products was raised on robust demand.
-
Q1 2025 saw robust revenue and profit growth, driven by strong overseas sales of Hemlibra and Actemra, with operating margin at 48.4%. Key pipeline advances include NXT007 and orforglipron, while uncertainties remain around U.S. tariffs and biosimilar launches.
Fiscal Year 2024
-
FY2024 saw record revenue and profit, driven by strong overseas sales, especially Hemlibra, offsetting domestic declines. The outlook for 2025 is positive, with continued growth expected from new products and a robust R&D pipeline, despite risks from generics and biosimilars.
-
Revenue declined due to the absence of RONAPREVE, but core business grew 10.9% year-over-year, with operating profit and net income both rising over 10% on strong HEMLIBRA and ACTEMRA exports. Operating margin improved to 47.5%, and full-year guidance anticipates record profits.